PATHOGENETIC FOUNDATIONS AND EVALUATION OF CLINICAL EFFICACY OF PROBIOTIC THERAPY IN THE COMPLEX TREATMENT OF SUPERFICIAL BLADDER CANCER
Keywords:
Non-muscle-invasive bladder cancer, probiotic therapy, transurethral resection, reparative regeneration, local immunity, immunohistochemistry, Ki-67, CD8+, mathematical prediction modelAbstract
The study involved 212 patients with superficial bladder cancer (NMIBC). The objective was to evaluate the impact of perioperative probiotic therapy (Lactobacillus acidophilus and E. coli M17) on urothelial regeneration and local immune status (CD8+, Ki-67). The results demonstrated that correcting immunological imbalance via probiotics significantly reduces recurrence rates. The developed 24-parameter mathematical model allows for the prediction of recurrence risk with an accuracy of over 85%.
References
Babakulov, S., Baymakov, S., Boltaev, S., Yunusov, S., & Hodiev, H. (2022). The use of probiotics in the complex treatment of bladder cancer. MedUnion, (1), 208-214.
Hamrаkulovich, B. S., Navruzovich, N. S., & Hamidullaevna, B. S. (2016). The basics of local clinical manifestations of superficial bladder cancer. European science review, (9-10), 75-77.
Hamrokulovich, B. S., Reyimberganovich, T. M., & Hamidullaevna, B. S. (2016). Specificity of micro-vascular density in superficial bladder cancer. European science review, (3-4), 63-64.
Kamat A. M., et al. (2021). Evidence-Based Management of Non-Muscle-Invasive Bladder Cancer. Nature Reviews Urology, 18(3), 135-153.
Lamm D. L., et al. (2000). Maintenance Bacillus Calmette-Guérin Immunotherapy for Recurrent TA, T1 and Carcinoma in Situ Transitional Cell Carcinoma of the Bladder: A Randomized Southwest Oncology Group Study. Journal of Urology, 163(4), 1124-1129.
Shapiro A., et al. (2023). The Role of Probiotics in the Modulation of the Urothelial Immune Response. Frontiers in Immunology, 14, 112-128.
Sylvester R. J., et al. (2006). Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. European Urology, 49(3), 466-475.
Zhu, H., et al. (2022). Immunohistochemical Analysis of Ki-67 and CD8+ Expression in Bladder Cancer: Clinical Implications. Oncology Letters, 23(5), 158-164.
Бабакулов, Ш. Х., Тангриберганов, М. Р., & Бабакулова, Ш. Х. (2016). Характеристика микрососудистого русла в зависимости от прогностических факторов при поверхностном раке мочевого пузыря. Журнал теоретической и клинической медицины, (3), 142-144.
Наврузов, С. Н., & Бабакулов, Ш. Х. (2013). СРАВНИТЕЛЬНАЯ ОЦЕНКА РЕЗУЛЬТАТОВ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ ПОВЕРХНОСТНОГО РАКА МОЧЕВОГО ПУЗЫРЯ. Новый день в медицине, (3), 41-44.
Тилляшайхов, М., Хасанов, Ш., Абдикаримов, М., Бабакулов, Ш., & Абдусаматов, Н. (2012). Современные подходы деривации мочи после радикальной цистэктомии при раке мочевого пузыря. Журнал вестник врача, 1(03), 179-182.
